Summary of minutes of EUCAST Steering Committee Meeting
Vienna, Austria, 13-14 April 2010

Attending
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Canton RC Clinical Data Co-ordinator Spain
Dr Christian Giske CG SRGA Sweden
Dr Antti Hakanen AH EUCAST Finland
Prof Gunnar Kahlmeter GK Chairperson Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Prof Arne Rodloff AR DIN Germany
Dr Martin Steinbakk MS NWGA Norway
Prof Paul Tulkens PT EUCAST Belgium

Apologies
Prof Claude-James Soussy CS CA-SFM France

Present for item 7, AFST subcommittee members
Dr Maiken Cavling Arendrup MA Denmark
Dr Manuel Cuenca-Estrella MC Spain
Dr Juan Luis Rodriguez-Tudela JR Spain (Chair)

1 Chairman’s welcome
2 Minutes of meeting of 8-9 February 2010 The minutes were accepted as a correct record.
3 Matters arising from minutes of 8-9 February 2010
A paper for CMI explaining ECOFFs is to be prepared.
MIC data on anaerobes, H. pylori and mycobacteria are being collected.
The new version of EUCAST Expert Rules and associated publications should be available soon.
4 New drugs Ceftobiprole license has been refused by EMA. See EMA website for details.
A response from the company is awaited to breakpoints proposed for a new glycopeptide.
5 Status of EUCAST rationale documents The status and content of several documents was reviewed.
Metronidazole and nitrofurantoin documents have been released. Vancomycin,
tecloplatin, erythromycin, clarithromycin and colistin documents are very close to completion.
6 Breakpoints/ expert rules for ESBLs There were no comments on recent proposals, which were
finalised, i.e. cefotaxime and ceftriaxone S≤1, R>2 mg/L, ceftazidime, cefepime and aztreonam
S≤1, R >4 mg/L, susceptibility to be reported as found. Expert rules will be changed accordingly.
7 Expert rules subcommittee The revised version of the expert rules document will be finalised.
8 Antifungal susceptibility testing subcommittee A joint meeting with subcommittee members
discussed current and future activities.
9 Anaerobe subcommittee A study of different susceptibility testing methods is underway.
10 Organisms without EUCAST breakpoints Meetings will be organised with Helicobacter and C.
difficile study groups. Work is planned or underway on Campylobacter, Legionella, Listeria and
Pasteurella multocida.
11 Breakpoints for mupirocin Following discussion of comments on proposals for breakpoints of
S≤2, R >256 mg/L, it was agreed to consult on revised proposals for S≤1, R >256 mg/L.
12 Breakpoints for colistin Breakpoints for P. aeruginosa of S≤4, R >4 mg/L were widely supported
in the recent consultation and were agreed.
13 ECCMID The ECCMID 2010 workshop, symposium, meet the experts session, debate on ESBLs
and General Committee Meeting went well and were very well attended. Topics proposed for the ECCMID 2011 meeting will be sent to the organising committee.

The Postgraduate course on susceptibility testing and resistance surveillance will be in Madrid, Monday 27 to Thursday 30 September 2010.

14 **CLSI** The proposed carbapenem addendum to the 2010 breakpoints is awaited.

15 **ECDC** The next Steering Committee meeting in Stockholm will be partly held at ECDC.

16 **EMA** Draft EMA guidance for industry on the data needed for registration of new antibacterial drugs has been distributed for comment. EMA will be invited to attend the Stockholm meeting to discuss the draft and other issues.

17 **Implementation of EUCAST breakpoints** A document on the readiness of commercial manufacturers to implement EUCAST breakpoints will be posted on the EUCAST website. Updated breakpoint and QC tables are close to completion. A question and answer file for the disk diffusion method is being prepared.

18 **New tetracycline agent** A preliminary presentation was given by the company.

19 **Agents without breakpoints** Agents to be given breakpoints were reviewed. Data will be collected for the 20 agents given priority.

20 **Oxacillin breakpoints for coagulase-negative staphylococci** More MIC distributions are needed specifically for *S. saprophyticus*.

21 **New macrocyclic agent** Breakpoints were discussed.

22 **Breakpoint format for the intermediate category** S is ≤x mg/L, R is >y mg/L, I is >x to y mg/L; eg for imipenem with Enterobacteriaceae S is ≤2 mg/L, R is >8 mg/L, I is >2 to 8 mg/L.

23 **Meaning of “-” and “IE” in breakpoint tables** “-” means that the agent should not be used. In place of – it could be reported resistant. “IE” means that the organism could be a target but that there is no evidence of efficacy. In place of IE an MIC could be reported, with or without comment.

24 **Carbapenem breakpoints for beta-haemolytic streptococci** For consistency, it was agreed to remove carbapenems breakpoints and add the same note as used for other beta-lactams.

25 **Any other business**
Steering Committee structure will need to be reviewed in the future as multiple countries set up national antibiotic committees and their representation might be increased.

Use of EUCAST website is increasing rapidly (recently 17,000 hits per month).

Dr Bob Rennie gave a presentation on a method of biofilm susceptibility testing.

AH and PT have completed their terms of office on the Steering Committee and were thanked for their very significant contributions.

26 **Next meetings**
- 5-6 July 2010, Stockholm, Sweden.
- 26-27 September 2010, Madrid, Spain.
- 22-23 November 2010, Basel, Switzerland.
- 14-15 February 2011, Vienna, Austria.
- 10-11 May 2011, Milan, Italy (after ECCMID).
- 5-6 September 2011, Munich, Germany